Regular use of fish oil supplements might increase, rather than lessen, the risk of first time heart disease and stroke among those in good cardiovascular health, but may slow progression of existing poor cardiovascular health and lower the risk of death, suggest the results of a large long term study, published in the open access journal BMJ Medicine.
Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says
Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables,
December 5, 2024